Cybin CEO to Discuss Next-Gen Neuropsychiatric Treatments at H.C. Wainwright Conference
Summary
Full Article
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference. The event, scheduled for June 16–17, 2025, will focus on advancing next-generation neuropsychiatric treatments. Cybin is at the forefront of developing psychedelic-based therapeutics to address the significant unmet needs in mental healthcare.
The company's innovative approach includes the development of CYB003, a proprietary deuterated psilocybin analog for major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder. These efforts are supported by a network of world-class partners and scientists, aiming to transform the treatment landscape for mental health conditions.
Cybin's participation in the conference underscores the growing interest and investment in psychedelic-based treatments as viable options for mental health care. The implications of Cybin's work extend beyond the pharmaceutical industry, offering hope for millions suffering from mental health conditions worldwide. For more details on Cybin's groundbreaking research and development, visit https://ibn.fm/aulG6.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)